AUSTIN, Texas, April 1, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, announced the results of a study1 to examine both total and donor-derived ...
A DNA screening to look for fetal abnormalities can render some unexpected results. According to a new analysis, a cell-free DNA screening to test for chromosomal disorders can also reveal undetected ...
Validation study published in the Journal of the American Society of Nephrology (JASN) showed improved sensitivity with quantification vs. dd-cfDNA fraction alone AUSTIN, Texas, Sept. 9, 2021 ...
Researchers at the National Institutes of Health (NIH) found previously undetected cancers in 48.6% of pregnant people who had abnormal results for prenatal cell-free DNA (cfDNA) testing used to ...
In 2013, researchers reported an eye-opening case of a healthy pregnant woman with a puzzling prenatal test result. A routine genetic screen using cell-free DNA—a highly accurate blood test—suggested ...
IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a diagnostics technology company, today announced additional favorable data regarding its lead assay VitaGraft™, which ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) ...
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results